Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid
Authors:
- Susan M. LandauSLSusan M. Landau
- Ming LuMLMing Lu
- Abhinay D. JoshiAJAbhinay D. Joshi
- Michael PontecorvoMPMichael Pontecorvo
- Mark A. MintunMMMark A. Mintun
- John Q. TrojanowskiJTJohn Q. Trojanowski
- Leslie M. ShawLSLeslie M. Shaw
- William J. JagustWJWilliam J. Jagust
- For The Alzheimer'S Disease Neuroimaging InitiativeFIFor The Alzheimer'S Disease Neuroimaging Initiative
- 28 March 2013
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 74 (6) , 826-836
Abstract
Objective: We examined agreement and disagreement between 2 biomarkers of β‐amyloid (Aβ) deposition (amyloid positron emission tomography [PET] and cerebrospinal fluid [CSF] Aβ1–42) in normal aging and dementia in a large multicenter study.Methods: Concurrently acquired florbetapir PET and CSF Aβ were measured in cognitively normal, mild cognitive impairment (MCI), and Alzheimer's disease participants (n = 374) from the Alzheimer's Disease Neuroimaging Initiative. We also compared Aβ measurements in a separate group with serial CSF measurements over 3.1 ± 0.8 years that preceded a single florbetapir session. Additional biomarker and cognitive data allowed us to further examine profiles of discordant cases.Results: Florbetapir and CSF Aβ were inversely correlated across all diagnostic groups, and dichotomous measurements were in agreement in 86% of subjects. Among subjects showing the most disagreement, the 2 discordant groups had different profiles: the florbetapir+/CSF Aβ−group was larger (n = 13) and was made up of only normal and early MCI subjects, whereas the florbetapir−/CSF Aβ+group was smaller (n = 7) and had poorer cognitive function and higher CSF tau, but no ApoE4 carriers. In the longitudinal sample, we observed both stable longitudinal CSF Aβ trajectories and those actively transitioning from normal to abnormal, but the final CSF Aβ measurements were in good agreement with florbetapir cortical retention.Interpretation: CSF and amyloid PET measurements of Aβ were consistent in the majority of subjects in the cross‐sectional and longitudinal populations. Based on our analysis of discordant subjects, the available evidence did not show that CSF Aβ regularly becomes abnormal prior to fibrillar Aβ accumulation early in the course of disease. Ann Neurol 2013;74:826–836Keywords
Funding Information
- NIH (U01 AG024904, P30 AG010129, K01 AG030514)
- National Institute on Aging and National Institute of Biomedical Imaging and Bioengineering
This publication has 36 references indexed in Scilit:
- Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control studyThe Lancet Neurology, 2012
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Amyloid deposition, hypometabolism, and longitudinal cognitive declineAnnals of Neurology, 2012
- CSF biomarkers cutoffs: the importance of coincident neuropathological diseasesActa Neuropathologica, 2012
- Evidence for Ordering of Alzheimer Disease BiomarkersArchives of Neurology, 2011
- Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization InitiativeAlzheimer's & Dementia, 2011
- CSF markers for incipient Alzheimer's diseaseThe Lancet Neurology, 2003
- CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy studyNeurology, 2003
- Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's diseaseAnnals of Neurology, 1995
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984